Trials / Completed
CompletedNCT01068860
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
A Multi-center, Double-blind, Placebo-controlled, Randomized Study to Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes Treated With Differing Baseline Diabetes Therapies
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 246 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
This was a 10-week, placebo-controlled, randomized study to investigate the effect of injectable IL-1B antagonist, Canakinumab , in participants with impaired glucose tolerance or Type 2 Diabetes Mellitus (T2DM) already treated on different background diabetes therapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Canakinumab 150 mg | Single subcutaneous injection of Canakinumab 150 mg. |
| DRUG | Placebo to Canakinumab | Single subcutaneous injection of Placebo to Canakinumab. |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2010-08-01
- Completion
- 2010-08-01
- First posted
- 2010-02-15
- Last updated
- 2011-09-05
- Results posted
- 2011-09-05
Locations
52 sites across 7 countries: United States, Australia, Canada, Finland, Germany, India, Italy
Source: ClinicalTrials.gov record NCT01068860. Inclusion in this directory is not an endorsement.